Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Kevin J Harrington"'
Autor:
F. Stephen Hodi, Kevin J. Harrington, Archie N. Tse, David C. Madoff, Jason J. Luke, Andrea Marie Perrone, Lawrence H. Schwartz, Anuradha D. Khilnani, Robert H.I. Andtbacka, Aurélien Marabelle, Gregory V. Goldmacher
Publikováno v:
Journal of Clinical Oncology
3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response
Autor:
Jessica Bauman, Irene Brana, Robert I. Haddad, Maria Jose Flor, Stephan Hackenberg, Sung-Bae Kim, Keith C. Bible, Pol Specenier, Nabil F. Saba, Bridget Martell, Lisa Licitra, Francis P. Worden, Binaifer Balsara, David S. Hong, Catherine Scholz, Jérôme Fayette, Kevin J. Harrington, Deborah J. Wong, Valentina Boni, Sjoukje F. Oosting, Allan L. Ho, Caroline Even, Antonio Gualberto, Myung-Ju Ahn, Ioanna Nixon, Mollie Leoni
Publikováno v:
Journal of Clinical Oncology. 39:3192-3192
Autor:
Helen Adderley, Rami Rauch, Laura Feeney, Kevin J. Harrington, Robert Metcalf, Elad Herz, Guy N J Betts, Brindley Sonal Hapuarachi, David H. J. Morgan, Russell W. Walker, Sam Rack
Publikováno v:
Journal of Clinical Oncology. 39:6072-6072
6072 Background: ACC is a rare salivary cancer for which effective drug therapies remain lacking. The highest rates of disease recurrence are in patients with NOTCH pathway activation, which is reported in 10-20% of ACC tumors. Novel drugs targeting
Autor:
Ezra E.W. Cohen, Danny Rischin, Burak Gumuscu, Kevin J. Harrington, Nicolas Mach, Lillian L. Siu, Beatriz Castelo, Anthony Kong, Jason Chesney, Hoi-Shen Radcliffe, Wendy Snyder
Publikováno v:
Journal of Clinical Oncology. 39:6036-6036
6036 Background: T-VEC, a genetically modified herpes simplex virus-1, is the first FDA- and EMA-approved oncolytic viral immunotherapy designed to enhance systemic antitumor immune responses. R/M HNSCC is a disease with considerable clinical complex
Autor:
Jean-Pascal Machiels, Amanda Psyrri, Robert I. Haddad, Lisa Licitra, Justine Yang Bruce, Douglas Adkins, Myung-Ju Ahn, Binaifer Balsara, Maura L. Gillison, Alan Loh Ho, Hung-Ming Wang, Ching Yun Hsieh, Nabil F. Saba, Kevin J. Harrington, Mollie Leoni
Publikováno v:
Journal of Clinical Oncology. 39:TPS6087-TPS6087
TPS6087 Background: Head and neck squamous cell carcinoma (HNSCC) accounts for more than 830,000 new cancer cases each year worldwide. The prognosis for recurrent and/or metastatic (R/M) HNSCC patients remains poor with an estimated median overall su
Autor:
Ramona F. Swaby, Barbara Burtness, Lisa Licitra, Makoto Tahara, Jean-Pascal Machiels, Ezra E.W. Cohen, Danny Rischin, Lillian L. Siu, Cecilia Pinheiro, Kevin J. Harrington, Ying Zhu, Chooi Peng Lee
Publikováno v:
Journal of Clinical Oncology. 38:TPS6589-TPS6589
TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of pembrolizumab plus
Autor:
Neus Baste, Prakash Neupane, Richard Greil, Tamara Rordorf, Thorsten Fuereder, Ricard Mesia, Barbara Burtness, Åse Bratland, Gilberto de Castro, Burak Gumuscu, Kevin J. Harrington, Makoto Tahara, Wan Zamaniah Wan Ishak, Brett G.M. Hughes, Ramona F. Swaby, Nuttapong Ngamphaiboon, Danny Rischin, Denis Soulières, Amanda Psyrri, Yayan Zhang
Publikováno v:
Journal of Clinical Oncology. 38:6505-6505
6505 Background: 1L P vs E improved OS in PD-L1 CPS ≥20 and CPS ≥1 populations, and led to noninferior OS in the total population, with favorable safety; 1L P+C vs E had superior OS in CPS ≥20, CPS ≥1, and total populations with comparable sa
Autor:
Khaireah Mubarak, Robert Metcalf, Guy N J Betts, Samuel Rack, David H. J. Morgan, Becky Bola, Kevin J. Harrington, Andrew J Wallace, Tracy Hussell
Publikováno v:
Journal of Clinical Oncology. 38:6585-6585
6585 Background: TP53 mutations are reported in 5% of patients with adenoid cystic carcinoma (ACC). Whilst TP53 mutations are associated with adverse clinical outcomes across multiple tumour types, their prognostic significance in ACC is unknown. We
Autor:
Joseph Elassal, Anna C. Pavlick, Adel Samson, Kevin J. Harrington, Jiaxin Niu, Francesca Aroldi, Robert S. Coffin, Alex Deterding, Scott Baum, Tawnya L. Bowles, Brendan D. Curti, Douglas Earl Laux, Mohammed M. Milhem, Joseph J. Sacco, Anna Olsson-Brown, Jason Chesney, Praveen K. Bommareddy, Mark R. Middleton, Ari M. Vanderwalde, Terence Duane Rhodes
Publikováno v:
Journal of Clinical Oncology. 38:e22050-e22050
e22050 Background: RP1 is an oncolytic HSV that encodes a fusogenic GALV-GP R- protein and GM-CSF. RP1 demonstrated tolerable safety and tumor regression alone and with nivolumab (nivo) in ph 1 in patients (pts) with a number of tumor types. To furth
Autor:
Prakash Neupane, Ricard Mesia, Jianxin Lin, Gilberto de Castro, Åse Bratland, Wan Zamaniah Wan Ishak, Danny Rischin, Brett G.M. Hughes, Richard Greil, Nuttapong Ngamphaiboon, Amanda Psyrri, Ramona F. Swaby, Tamara Rordorf, Burak Gumuscu, Kevin J. Harrington, Thorsten Fuereder, Makoto Tahara, Denis Soulières, Neus Baste, Barbara Burtness
Publikováno v:
Journal of Clinical Oncology. 38:6530-6530
6530 Background: In the phase 3 KEYNOTE-048 trial ( NCT02358031 ) in R/M HNSCC (N = 882), 1L P vs E showed superior OS in PD-L1 CPS ≥20 and CPS ≥1 populations, noninferior OS in the total population, no PFS benefit, and favorable safety; 1L P+C v